Accueil・Liste d'Actions・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Fermé

SecteurSoins de santé

85.15 -1.95

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

86.84

Max

90.31

Chiffres clés
By Trading Economics
Revenu	-51M -184M
Ventes	1.5M 75M
P/E Moyenne du Secteur	47.744 57.002
BPA	-1.36
Marge bénéficiaire	-244.188
Employés	711
EBITDA	-47M -154M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+25.8% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	362M 12B
Ouverture précédente	87.1
Clôture précédente	85.15

Sentiment de l'Actualité

By Acuity

20%

80%

32 / 340 Classement par Healthcare

Arrowhead Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 août 2026, 21:01 UTC

Arrowhead Pharmaceuticals shares are higher in after-market hours, buoyed by positive market sentiment following comments on interest rates from Economic Advisor Phelan.

11 août 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher today, remaining above its 20-day moving average amid geopolitical tensions and anticipation of U.S. inflation reports.

6 août 2026, 19:16 UTC

Arrowhead Pharmaceuticals Inc shares are lower during Thursday's session, despite earlier rebounding from a session high. No specific news was identified to explain the decline.

5 août 2026, 21:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in after-market hours, reflecting strong performance and positioning above its 20-day moving average.

4 août 2026, 23:02 UTC

Social Media

News

Arrowhead Pharmaceuticals shares fell in after-market trading following a net loss of $194.280 million and an EPS of -$1.36 in its fiscal Q3 results.

3 août 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in Monday's session. Broader market positivity follows President Trump's military announcement, impacting crude oil prices.

31 juil. 2026, 19:16 UTC

Correlated Moves

Arrowhead Pharmaceuticals shares are lower, reflecting broader pressures in the biotechnology sector amid rising inflation concerns linked to increased crude oil prices.

30 juil. 2026, 23:06 UTC

Arrowhead Pharmaceuticals Inc shares declined in after-market trading, with no specific news identified to explain the movement amid broader market volatility.

29 juil. 2026, 20:09 UTC

News

Social Media

RBC Capital raised Arrowhead Pharmaceuticals' price target to $100 from $87, contributing to positive sentiment and modest gains since Tuesday's close.

28 juil. 2026, 23:31 UTC

Arrowhead Pharmaceuticals shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and significant declines in other indices.

27 juil. 2026, 19:02 UTC

News

Social Media

Event

Arrowhead Pharmaceuticals completed enrollment in its Phase 3 YOSEMITE trial for zodasiran, with H.C. Wainwright and Morgan Stanley raising price targets to $115 and $120, respectively.

24 juil. 2026, 19:12 UTC

Social Media

Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $120, but shares are trading lower amid increased market volume during Friday's session.

23 juil. 2026, 10:16 UTC

News

Event

Arrowhead Pharmaceuticals shares rise in pre-market trading, building on Wednesday's gains after positive drug trial results and a price target increase to $115 from $90.

22 juil. 2026, 22:06 UTC

Event

Arrowhead Pharmaceuticals reported positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies, boosting shares higher in after-market trading.

21 juil. 2026, 20:12 UTC

Arrowhead Pharmaceuticals Inc. shares declined in after-market trading, remaining below the 20-day moving average and near the lower end of the one-month range.

20 juil. 2026, 20:21 UTC

Arrowhead Pharmaceuticals Inc shares are lower in after-market hours, declining from a high to a low amid unusual trading activity and no specific news identified.

Comparaison

Variation de prix

Arrowhead Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

25.8% hausse

Prévisions sur 12 Mois

Moyen 109.76 USD 25.8%

Haut 126 USD

Bas 89.59 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

Achat

Maintien

Vente

Basé sur 10 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

32 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.